ReviewThe Journal of clinical and aesthetic dermatology2023
Topical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation.
Review in The Journal of clinical and aesthetic dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a novel topical immunomodulatory therapy for psoriasis: bridging the therapeutic gap in moderate disease.Extracellular vesicles and circulating nucleic acids · 2026Review
- Psoriasis, stem cells, and obesity: metabolic exploration for therapeutics.Journal of medicine and life · 2025Review
- Therapeutic Advancements in Psoriasis and Psoriatic Arthritis.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While corticosteroids and a limited number of nonsteroidal agents have formed the basis for United States Food and Drug Administration (FDA)-approved topical treatments of plaque psoriasis, there remains a need for efficacious nonsteroidal topical therapies in patients with psoriasis who cannot tolerate, do not respond well to, or wish to avoid topical corticosteroid therapy. Aryl hydrocarbon receptor (AhR) modulation has been shown to be an effective mechanism of action in the topical treatment of psoriasis. Currently there is only one FDA-approved, nonsteroidal, topical AhR modulating agent for the treatment of psoriasis. This educational activity seeks to broaden the treatment knowledge of the practicing dermatology community and inform them on the use of topical AhR modulating therapy as an addition to the advancing treatment armamentarium for patients with psoriasis.
Identifiers
38496799PMC10939505W4394760398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.